- The disease
- Dengue fever is a mosquito-borne viral illness caused by any of four dengue virus serotypes (DENV-1 through DENV-4). It affects an estimated hundreds of millions of people annually across tropical and subtropical regions, though a precise current figure would require a cited source. Severe dengue can progress to plasma leakage, organ impairment, and haemorrhage. There is currently no approved antiviral treatment for dengue fever.
- What the asset is trying to do
- ISLA-101 is an oral formulation of fenretinide, a synthetic retinoid (a compound in the vitamin A family). Fenretinide is described by Island Pharmaceuticals as a broad-spectrum antiviral small molecule. Unlike vaccines, which aim to prevent infection by inducing an immune response to a specific serotype, fenretinide's antiviral mechanism is reported to be direct, though the precise molecular target in dengue virus replication has not been disclosed in the input data provided.
- What the trial is measuring, and why it matters
- The Phase 2 trial (NCT06528457) used a dengue live-virus human challenge model, in which healthy volunteers are deliberately exposed to a controlled dose of DENV-1 to allow evaluation of a drug's effect under defined conditions (per ClinicalTrials.gov NCT06528457). The study enrolled 15 subjects in prophylactic and treatment arms compared against placebo (per ClinicalTrials.gov NCT06528457). Human challenge models allow early assessment of antiviral activity in a small, controlled cohort before larger field trials.
- Efficacy benchmarks in this setting
- There is no approved antiviral drug for dengue against which a direct efficacy benchmark can be drawn. For clinical context, the approved dengue vaccine Dengvaxia (CYD-TDV) demonstrated efficacy of approximately 65.6% against symptomatic dengue in seropositive participants in Phase 3 trials (Sridhar et al, New England Journal of Medicine, 2018). A second approved vaccine, Qdenga (TAK-003), showed vaccine efficacy of 73.3% against symptomatic dengue in a Phase 3 trial at 12 months (Tricou et al, Lancet, 2023). These figures come from large randomised controlled trials in field settings and are not statistically comparable to results from a 15-subject human challenge study of ISLA-101.
- Commercial context
- There is no approved antiviral treatment for dengue fever; the approved products in dengue are prophylactic vaccines (Dengvaxia and Qdenga). ISLA-101 (fenretinide) in dengue is Island Pharmaceuticals' lead clinical programme, based on the company's public disclosures. Island announced an antiviral pipeline expansion through a strategic collaboration in March 2026 (per ASX announcement, 8 March 2026), though the financial terms of that collaboration are not available in the input data. The company has also announced activities related to a separate asset, Galidesivir, in a biodefence context (per ASX announcements, June 2026).